- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Preoperative management of gastrointestinal and pulmonary medications: SPAQI consensus statement
![Preoperative management of gastrointestinal and pulmonary medications: SPAQI consensus statement Preoperative management of gastrointestinal and pulmonary medications: SPAQI consensus statement](https://medicaldialogues.in/h-upload/2021/11/03/750x450_163253-medication-management.webp)
USA: The Society for Perioperative Assessment and Quality Improvement (SPAQI) has released a consensus statement on the preoperative management of gastrointestinal and pulmonary medications. The guideline was published in the journal Mayo Clinic Proceeding on November 01, 2021.
Perioperative medication management is important to preoperative optimization but remains challenging due to the lack of literature guidance. Published recommendations are based on the expert opinion of a small number of authors without collaboration from multiple specialties. The SPAQI recognized the need for consensus recommendations in this area as well as the unique opportunity for its multidisciplinary membership to fill this void.
The aim of this consensus statement is to provide practical guidance on the preoperative management of gastrointestinal and pulmonary medications. A panel of experts with anesthesiology, perioperative medicine, hospital medicine, general internal medicine, and medical specialty experience was drawn together and identified the common medications in each of these categories. Kurt J. Pfeifer, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, and the team then used a modified Delphi approach to review the literature and to generate consensus recommendations.
The group derived consensus recommendations using the following guiding principles:
- Preference is given to not interrupting therapy unless there are potential risks fromcontinuation.
- Focus is placed on management of long-term medications.
- Preoperative initiation of therapy, supplemental treatment (eg, "stress dose steroids"), and postoperative management are outside the scope of this paper.
- Long-term oral corticosteroid management is covered in another publication within this series, entitled "Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement.
Consensus was established for all reviewed medications, and the completed set of recommendations was reviewed and approved by the Executive Committee of SPAQI. Described here are specific recommendations for each medication class.
Pulmonary Medications
- Continue inhaled anticholinergic medications up to and including the day of surgery.
- Continue inhaled β2-adrenergic agonists up to and including the day of surgery.
- Continue theophylline before the day of surgery but hold on the day of surgery because of its narrow therapeutic window, potential for drug interactions, and cardiac adverse effects. Consider discussion of long-term necessity with the prescriber.
- Continue roflumilast up to and including the day of surgery.
- Continue inhaled corticosteroids up to and including the day of surgery.
- Continue combination inhaled medications up to and including the day of surgery.
- Continue leukotriene inhibitors up to and including the day of surgery.
- Continue N-acetylcysteine up to and including the day of surgery.
- Continue antihistamines before the day of surgery but hold first-generation antihistamines and cetirizine on the day of surgery because of their potential for contributing to postoperative delirium and anticholinergic adverse effects.
- Continue arylalkylamine decongestants before the day of surgery but hold on the day of surgery because of their potential for contributing to cardiovascular adverse effects.
- Continue prostacyclin analogues up to and including the day of surgery.
- Continue selexipag up to and including the day of surgery.
- Continue endothelin receptor antagonists up to and including the day of surgery.
- Continue PDE-5 inhibitors up to and including the day of surgery when used for treatment of PH. Perioperative management of PDE-5 inhibitors prescribed for urologic indications is detailed in another publication within this consensus statement series.
- Continue riociguat up to and including the day of surgery, but discuss potential for bleeding complications with the surgeon or proceduralist.
- Continue nintedanib and pirfenidone up to and including the day of surgery, but discuss perioperative management with the surgeon and prescribing clinician.
Gastrointestinal Medications
- Continue proton pump inhibitors (PPIs) up to and including the day of surgery.
- Continue H2 receptor antagonists up to and including the day of surgery.
- Continue antacids up to the day before surgery but hold on the morning of surgery. Nonparticulate antacids may be acceptable to take on the morning of surgery for patients at increased risk for pulmonary aspiration.
- Continue 5-HT3 antagonists up to and including the day of surgery.
- Continue dopamine antagonists up to and including the day of surgery, unless there are concerns of significant QT prolongation.
- Continue aprepitant up to and including the day of surgery.
- Continue entecavir, tenofovir, lamivudine, and adefovir up to and including the day of surgery but consult with the prescribing clinician. Assess renal and hepatic function before surgery because of nephrotoxicity and hepatotoxicity of these agents.
- When interferons are used for treatment of viral hepatitis, stop them 1 to 2 weeks before surgery because of potential for perioperative complications but consult with the prescribing clinician.
- Continue ribavirin up to the day of surgery but hold on the morning of surgery. If hemoglobin level has not recently been obtained, check it before surgery.
- Continue sofosbuvir and ledipasvir/sofosbuvir up to and including the day of surgery. Continue sofosbuvir/valpatasvir, glecaprevir/pibrentasvir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, and sofosbuvir/velpatasvir/voxilaprevir up to the day of surgery but hold on the morning of surgery. Discuss management with the patient's gastroenterology clinician.
- Continue gallstone solubilizing agents up to the day before surgery but hold on the morning of surgery.
- Continue pancreatic enzymes up to the day before surgery but hold on the morning of surgery.
- Continue 5-aminosalicylic acid medications up to and including the day of surgery but consider holding on the morning of surgery if glomerular filtration rate is below 50 mL/min.
- Continue antidiarrheals up to the day before surgery but hold on the morning of surgery because of the risk of opioid agonism and anticholinergic effects.
- Continue anticholinergics and antispasmodics up to the day before surgery but hold on the morning of surgery. Reexamine the long-term necessity of these medications (especially in elderly patients). Continuation of these agents is reasonable if it is absolutely needed for airway secretion control that could affect airway management.
- Continue lubiprostone up to and including the day of surgery.
- Continue guanylate cyclase C agonists up to and including the day of surgery.
- Continue serotonergic neuroenteric modulators up to and including the day of surgery.
- Continue laxatives up to the day before surgery but hold on the morning of surgery.
- For patients taking these agents to prevent solid organ transplant rejection, continue up to and including the day of surgery. For other indications, management must be individualized on the basis of patient and surgical factors, and the risks and benefits of continuation must be discussed with the surgeon and prescribing clinician.
- Continue purine analogues up to and including the day of surgery but consult with the surgeon and prescribing clinician.
- Continue methotrexate up to and including the day of surgery but consult with the surgeon and prescribing clinician.
- Withhold TNF inhibitors for at least 1 dosing interval before surgery (ie, if taken every 4 weeks, schedule surgery 5 weeks after the last dose) but consult with the surgeon and prescribing clinician to discuss the relevant risks and benefits of therapy interruption.
- Withhold vedolizumab, ustekinumab, and natalizumab for at least 1 dosing interval before surgery. Withhold ozanimod for 60 days and facilitation for 7 days before surgery but consult with the surgeon and prescribing clinician to discuss the relevant risks and benefits of therapy interruption. For vedolizumab, perioperative continuation may be reasonable for nonabdominal surgery.
- Withhold phentermine for at least 4 days before surgery.
- Withhold lisdexamfetamine for 72 hours before surgery if it is being taken for binge eating disorder. For patients at high risk for relapse of binge eating disorder, the medication may be continued before surgery and held only on the morning of surgery, but this requires discussion with the prescriber and anesthesiologist.
- Withhold phentermine/topiramate for at least 4 days before surgery. Either wean the patient off the medication during the course of a week before surgery (according to product insert) or, while withholding, provide topiramate alone at the same dose.
- Continue orlistat up to the day before surgery but hold onthe morning of surgery.
- Before the day of surgery, continue GLP-1 agonists unless there is heightened concern for postoperative nausea, vomiting, or gut dysfunction (eg, gastrointestinal surgery). In these situations, consider holding 24 hours for once- or twice-daily preparations and up to 1 week before surgery for weekly preparations (including holding dose within 7 days beforesurgery). Withhold GLP-1 agonists on the morning of surgery. If a weekly dose is due on the morning of surgery, delay taking it until later in the day after surgery.
- Withhold bupropion/naltrexone for 72 hours before surgery if opioids are expected to be used preoperatively.
"This consensus statement provides recommendations of experts in anesthesiology, internal medicine, perioperative medicine, and medical subspecialties for the management of common pulmonary and gastrointestinal medications," wrote the authors.
Reference:
"Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement," is published in the journal Mayo Clinic Proceedings.
DOI: https://www.mayoclinicproceedings.org/article/S0025-6196(21)00633-9/fulltext
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751